+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B



Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B



Digestive Diseases and Sciences 52(3): 727-731



We sought to evaluate the long-term results of interferon-alpha (IFN-alpha) therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Eighty HBeAg-negative naive patients (62 men; mean age, 39.9 years) who received IFN-alpha for 6 months were studied. Alanine aminotransferase normalization with undetectable HBV-DNA by molecular hybridization was accepted as response. All patients but 1 were precirrhotic stage. At the end of treatment, 44 (55%) patients responded, and they were followed for a mean of 59.5 months (range, 18-132). Twenty-seven patients (61.4%) showed recurrence (63% in first year). Responses at 6 months and at the end of the follow-up period 42.5% and 30% (including 7 patients without end treatment response), respectively. Recurrence of HBV replication was not detected after the 2-years follow-up period. Histologic improvement was observed in 83.3% patients with end-of-follow-up response. HBsAg became negative in 4 patients (5%). On multivariate analysis, younger age (P = .04) and lower GGT level (P = .037) were independent factors for prediction of end-of-follow-up response. Nearly half of the patients with HBeAg-negative chronic hepatitis B responds to IFN-alpha at the end of therapy. Despite the high recurrence rates, response continues in about one third of patients after a mean of 59.5 months.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012989818

Download citation: RISBibTeXText

PMID: 17237999

DOI: 10.1007/s10620-006-9445-1


Related references

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 38(Suppl. 2): 169, 2003

Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Journal of Pharmaceutical Sciences 92(7): 1386-1395, 2003

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. Journal of Hepatology 34(2): 306-313, 2001

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 48(6): 341-349, 2005

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastro-Enterologica Belgica 70(1): 20-24, 2007

Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy. Journal of Hepatology 36(2): 280-282, 2002

Long term follow-up of Chinese patients with HBeAg-negative chronic hepatitis who discontinued treatment after 2 years of lamivudine monotherapy. 2007

Alpha-interferon induces HbeAg-chronic active liver disease but improves long-term survival in HBeAg+ chronic active hepatitis patients. Journal of Hepatology 28(Suppl. 1): 122, 1998

Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece. Alimentary Pharmacology and Therapeutics 24(3): 525-533, 2006

Long-term outcomes of thymosin-alpha1 and interferon beta-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Journal of Pharmaceutical Sciences 92(7): 1386-1395, 2003

The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B. Hepatology 30(4 Part 2): 343A, 1999

Long-term follow-up after initial response to interferon therapy in patients with HBeAg-negative chronic hepatitis B. Hepatology 32(4 Pt 2): 378A, 2000

Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa. Gastroenterology 120(5 Suppl. 1): A 572, 2001

Long-term follow-up of HBeAg-positive patients after interferon-alpha treatment for chronic hepatitis B. Zeitschrift für Gastroenterologie 35(3): 233-235, 1997